{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,5]],"date-time":"2026-09-05T18:45:25Z","timestamp":1788633925938,"version":"build-2803163510"},"reference-count":179,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["21877101"],"award-info":[{"award-number":["21877101"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["22177105"],"award-info":[{"award-number":["22177105"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Bioorganic Chemistry"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1016\/j.bioorg.2025.109238","type":"journal-article","created":{"date-parts":[[2025,11,16]],"date-time":"2025-11-16T05:48:59Z","timestamp":1763272139000},"page":"109238","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"special_numbering":"C","title":["PD-L1-targeted novel molecule design: recent advances in immunomodulatory technologies and emerging insights in Cancer therapy"],"prefix":"10.1016","volume":"167","author":[{"given":"Feng","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruyue","family":"Ni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liang","family":"Qian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zeyu","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shenwei","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annoor","family":"Awadasseid","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zengxuan","family":"Cai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuqiong","family":"Xiong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wen","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bioorg.2025.109238_bb0005","doi-asserted-by":"crossref","first-page":"315","DOI":"10.3389\/fonc.2018.00315","article-title":"Immuno-oncology: emerging targets and combination therapies","volume":"8","author":"Marshall","year":"2018","journal-title":"Front. Oncol."},{"key":"10.1016\/j.bioorg.2025.109238_bb0010","doi-asserted-by":"crossref","first-page":"8519","DOI":"10.1021\/acs.jmedchem.4c00568","article-title":"Emerging targets and therapeutics in Immuno-oncology: insights from landscape analysis","volume":"67","author":"Iyer","year":"2024","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bioorg.2025.109238_bb0015","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1038\/d41573-022-00030-4","article-title":"Challenges and opportunities in the PD1\/PDL1 inhibitor clinical trial landscape","volume":"21","author":"Upadhaya","year":"2022","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.bioorg.2025.109238_bb0020","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1038\/d41573-019-00182-w","article-title":"Trends in clinical development for PD-1\/PD-L1 inhibitors","volume":"19","author":"Xin Yu","year":"2020","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.bioorg.2025.109238_bb0025","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.1016\/j.drudis.2016.04.011","article-title":"From monoclonal antibodies to small molecules: the development of inhibitors targeting the PD-1\/PD-L1 pathway","volume":"21","author":"Zhan","year":"2016","journal-title":"Drug Discov. Today"},{"key":"10.1016\/j.bioorg.2025.109238_bb0030","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2019.111876","article-title":"Progress in PD-1\/PD-L1 pathway inhibitors: from biomacromolecules to small molecules","volume":"186","author":"Lin","year":"2020","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.bioorg.2025.109238_bb0035","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2021.113170","article-title":"Recent advance of peptide-based molecules and nonpeptidic small-molecules modulating PD-1\/PD-L1 protein-protein interaction or targeting PD-L1 protein degradation","volume":"213","author":"Pan","year":"2021","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.bioorg.2025.109238_bb0040","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41401-020-0366-x","article-title":"Small molecule inhibitors targeting the PD-1\/PD-L1 signaling pathway","volume":"42","author":"Wu","year":"2021","journal-title":"Acta Pharmacol. Sin."},{"key":"10.1016\/j.bioorg.2025.109238_bb0045","doi-asserted-by":"crossref","first-page":"1161","DOI":"10.1039\/D3MD00655G","article-title":"Progress in small-molecule inhibitors targeting PD-L1","volume":"15","author":"Xu","year":"2024","journal-title":"RSC Med. Chem."},{"key":"10.1016\/j.bioorg.2025.109238_bb0050","doi-asserted-by":"crossref","first-page":"5857","DOI":"10.1021\/acs.jmedchem.7b00293","article-title":"Small-molecule inhibitors of the programmed cell Death-1\/programmed death-ligand 1 (PD-1\/PD-L1) interaction via transiently induced protein states and dimerization of PD-L1","volume":"60","author":"Guzik","year":"2017","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bioorg.2025.109238_bb0055","unstructured":"S. WANG, Yuguang, ZHANG, Nong, WU, Tianzhi, HE, Min, WU, Xinliang, ZHANG, Aromatic ethylene compound and preparation method therefor, and intermediate, pharmaceutical composition, and application thereof, WO2022052926 (2022)."},{"key":"10.1016\/j.bioorg.2025.109238_bb0060","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3390\/pharmaceutics13050598","article-title":"Metabolism and interspecies variation of immh-010, a programmed cell death ligand 1 inhibitor prodrug","volume":"13","author":"Wang","year":"2021","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.bioorg.2025.109238_bb0065","first-page":"1","article-title":"Simultaneous determination of a novel PD-L1 inhibitor, IMMH-010, and its active metabolite, YPD-29B, in rat biological matrices by polarity-switching liquid chromatography-tandem mass spectrometry: application to ADME studies","volume":"12","author":"Jiang","year":"2021","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.bioorg.2025.109238_bb0070","doi-asserted-by":"crossref","first-page":"30323","DOI":"10.18632\/oncotarget.8730","article-title":"Structural basis for small molecule targeting of the programmed death ligand 1 (PD-L1)","volume":"7","author":"Zak","year":"2016","journal-title":"Oncotarget"},{"key":"10.1016\/j.bioorg.2025.109238_bb0075","doi-asserted-by":"crossref","first-page":"2276","DOI":"10.1038\/s41467-017-02258-w","article-title":"Protein conformational flexibility modulates kinetics and thermodynamics of drug binding","volume":"8","author":"Amaral","year":"2017","journal-title":"Nat. Commun."},{"key":"10.1016\/j.bioorg.2025.109238_bb0080","doi-asserted-by":"crossref","DOI":"10.1016\/j.bmc.2025.118238","article-title":"Advances in cancer immunotherapy using small-molecular inhibitors targeting the PD-1\/PD-L1 interaction","volume":"127","author":"Zhang","year":"2025","journal-title":"Bioorganic Med. Chem."},{"key":"10.1016\/j.bioorg.2025.109238_bb0085","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1038\/s41571-022-00601-9","article-title":"Mechanisms regulating PD-L1 expression in cancers and associated opportunities for novel small-molecule therapeutics","volume":"19","author":"Yamaguchi","year":"2022","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.bioorg.2025.109238_bb0090","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1038\/nrd3216","article-title":"Utilizing targeted cancer therapeutic agents in combination: novel approaches and urgent requirements","volume":"9","author":"Kummar","year":"2010","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.bioorg.2025.109238_bb0095","doi-asserted-by":"crossref","first-page":"7874","DOI":"10.1021\/jm5006463","article-title":"Polypharmacology: challenges and opportunities in drug discovery","volume":"57","author":"Anighoro","year":"2014","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bioorg.2025.109238_bb0100","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2021.105741","article-title":"Non-cytomembrane PD-L1: an atypical target for cancer","volume":"170","author":"Ying","year":"2021","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.bioorg.2025.109238_bb0105","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1038\/s41392-021-00463-0","article-title":"PD-L1 regulates genomic stability via interaction with cohesin-SA1 in the nucleus","volume":"6","author":"Zhang","year":"2021","journal-title":"Signal Transduct. Target. Ther."},{"key":"10.1016\/j.bioorg.2025.109238_bb0110","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1038\/s41421-023-00521-7","article-title":"Nuclear PD-L1 promotes EGR1-mediated angiogenesis and accelerates tumorigenesis","volume":"9","author":"Yu","year":"2023","journal-title":"Cell Discov."},{"key":"10.1016\/j.bioorg.2025.109238_bb0115","article-title":"Challenges Coexist with Opportunities: Spatial Heterogeneity Expression of PD-L1 in Cancer Therapy","volume":"11","author":"Wang","year":"2024","journal-title":"Adv. Sci. (Weinheim, Baden-Wurttemberg, Ger.)"},{"key":"10.1016\/j.bioorg.2025.109238_bb0120","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1186\/s12943-019-1074-3","article-title":"The role of exosomal PD-L1 in tumor progression and immunotherapy","volume":"18","author":"Xie","year":"2019","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.bioorg.2025.109238_bb0125","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1186\/s12943-020-1144-6","article-title":"Predictive biomarkers and mechanisms underlying resistance to PD1\/PD-L1 blockade cancer immunotherapy","volume":"19","author":"Ren","year":"2020","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.bioorg.2025.109238_bb0130","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2024.116267","article-title":"Recent advances and mechanisms of action of PD-L1 degraders as potential therapeutic agents","volume":"268","author":"Zhang","year":"2024","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.bioorg.2025.109238_bb0135","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1038\/s41573-021-00371-6","article-title":"PROTAC targeted protein degraders: the past is prologue","volume":"21","author":"B\u00e9k\u00e9s","year":"2022","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.bioorg.2025.109238_bb0140","doi-asserted-by":"crossref","first-page":"8091","DOI":"10.1021\/acs.jmedchem.2c00316","article-title":"Beyond proteolysis-targeting chimeric molecules: designing heterobifunctional molecules based on functional effectors","volume":"65","author":"Hua","year":"2022","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bioorg.2025.109238_bb0145","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/j.coph.2021.02.009","article-title":"Transforming targeted cancer therapy with PROTACs: a forward-looking perspective","volume":"57","author":"Farnaby","year":"2021","journal-title":"Curr. Opin. Pharmacol."},{"key":"10.1016\/j.bioorg.2025.109238_bb0150","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1021\/acsmedchemlett.9b00597","article-title":"PROTAC technology: opportunities and challenges","volume":"11","author":"Gao","year":"2020","journal-title":"ACS Med. Chem. Lett."},{"key":"10.1016\/j.bioorg.2025.109238_bb0155","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2023.115127","article-title":"Developments of PROTACs technology in immune-related diseases","volume":"249","author":"Wang","year":"2023","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.bioorg.2025.109238_bb0160","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2020.112981","article-title":"Proteolysis targeting chimera (PROTAC) in drug discovery paradigm: recent progress and future challenges","volume":"210","author":"Zeng","year":"2021","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.bioorg.2025.109238_bb0165","doi-asserted-by":"crossref","first-page":"1770","DOI":"10.1021\/acschembio.5b00216","article-title":"Selective small molecule induced degradation of the BET Bromodomain protein BRD4","volume":"10","author":"Zengerle","year":"2015","journal-title":"ACS Chem. Biol."},{"key":"10.1016\/j.bioorg.2025.109238_bb0170","doi-asserted-by":"crossref","DOI":"10.3389\/fchem.2021.707317","article-title":"E3 ligase ligands in successful PROTACs: an overview of syntheses and linker attachment points","volume":"9","author":"Bricelj","year":"2021","journal-title":"Front. Chem."},{"key":"10.1016\/j.bioorg.2025.109238_bb0175","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2023.115444","article-title":"Current advances of small molecule E3 ligands for proteolysis-targeting chimeras design","volume":"256","author":"Mi","year":"2023","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.bioorg.2025.109238_bb0180","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2023.116041","article-title":"Journey of Von Hippel-Lindau (VHL) E3 ligase in PROTACs design: from VHL ligands to VHL-based degraders","volume":"265","author":"Setia","year":"2024","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.bioorg.2025.109238_bb0185","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2020.112377","article-title":"Discovery of novel resorcinol diphenyl ether-based PROTAC-like molecules as dual inhibitors and degraders of PD-L1","volume":"199","author":"Cheng","year":"2020","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.bioorg.2025.109238_bb0190","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2021.104833","article-title":"In vitro and in vivo degradation of programmed cell death ligand 1 (PD-L1) by a proteolysis targeting chimera (PROTAC)","volume":"111","author":"Wang","year":"2021","journal-title":"Bioorg. Chem."},{"key":"10.1016\/j.bioorg.2025.109238_bb0195","article-title":"Design, synthesis, and evaluation of PD-L1 degraders to enhance T cell killing activity against melanoma","volume":"34","author":"Liu","year":"2023","journal-title":"Chinese Chem. Lett."},{"key":"10.1016\/j.bioorg.2025.109238_bb0200","doi-asserted-by":"crossref","DOI":"10.1016\/j.bmc.2024.117867","article-title":"Design, synthesis, anti-tumor activity and mechanism of novel PROTACs as degraders of PD-L1 and inhibitors of PD-1\/PD-L1 interaction","volume":"111","author":"Zhang","year":"2024","journal-title":"Bioorganic Med. Chem."},{"key":"10.1016\/j.bioorg.2025.109238_bb0210","doi-asserted-by":"crossref","first-page":"10589","DOI":"10.1021\/acs.jmedchem.3c02259","article-title":"Discovery of novel proteolysis-targeting chimera molecules as degraders of programmed cell death-ligand 1 for breast Cancer therapy","volume":"67","author":"Zhang","year":"2024","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bioorg.2025.109238_bb0215","article-title":"PD-L1\/SHP2 dual PROTACs inhibit melanoma by enhancing T-cell killing activity","volume":"36","author":"Liu","year":"2024","journal-title":"Chinese Chem. Lett."},{"key":"10.1016\/j.bioorg.2025.109238_bb0220","doi-asserted-by":"crossref","first-page":"21831","DOI":"10.1021\/jacs.2c08367","article-title":"Bifunctional compounds as molecular degraders for integrin-facilitated targeted protein degradation","volume":"144","author":"Zheng","year":"2022","journal-title":"J. Am. Chem. Soc."},{"key":"10.1016\/j.bioorg.2025.109238_bb0230","doi-asserted-by":"crossref","first-page":"3038","DOI":"10.1039\/D4MD00320A","article-title":"A novel hydrophobic tag leads to the efficient degradation of programmed death-ligand 1","volume":"15","author":"Gao","year":"2024","journal-title":"RSC Med. Chem."},{"key":"10.1016\/j.bioorg.2025.109238_bb0205","doi-asserted-by":"crossref","first-page":"10579","DOI":"10.1021\/acs.jmedchem.3c00731","article-title":"Design, synthesis, and antitumor activity evaluation of 2-Arylmethoxy-4-(2,2\u2032-dihalogen-substituted biphenyl-3-ylmethoxy) Benzylamine derivatives as potent PD-1\/PD-L1 inhibitors","volume":"66","author":"Zhang","year":"2023","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bioorg.2025.109238_bb0225","doi-asserted-by":"crossref","first-page":"3298","DOI":"10.1002\/anie.201707948","article-title":"An \u03b1v-RGD integrin inhibitor toolbox: drug discovery insight, challenges and opportunities","volume":"57","author":"Hatley","year":"2018","journal-title":"Angew. Chem. Int. Ed. Engl."},{"key":"10.1016\/j.bioorg.2025.109238_bb0235","doi-asserted-by":"crossref","DOI":"10.1016\/j.cclet.2023.109192","article-title":"Hydrophobic tag tethering degrader as a promising paradigm of protein degradation: past, present and future perspectives","volume":"35","author":"Ha","year":"2024","journal-title":"Chinese Chem. Lett."},{"key":"10.1016\/j.bioorg.2025.109238_bb0240","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1038\/s41586-019-1674-5","article-title":"VISTA is an acidic pH-selective ligand for PSGL-1","volume":"574","author":"Johnston","year":"2019","journal-title":"Nature"},{"key":"10.1016\/j.bioorg.2025.109238_bb0245","doi-asserted-by":"crossref","DOI":"10.1016\/j.drudis.2024.104045","article-title":"VISTA: a novel checkpoint for Cancer immunotherapy","volume":"29","author":"Gao","year":"2024","journal-title":"Drug Discov. Today"},{"key":"10.1016\/j.bioorg.2025.109238_bb0250","doi-asserted-by":"crossref","first-page":"2509","DOI":"10.1016\/j.celrep.2019.07.073","article-title":"Structure and functional binding epitope of V-domain Ig suppressor of T cell activation","volume":"28","author":"Mehta","year":"2019","journal-title":"Cell Rep."},{"key":"10.1016\/j.bioorg.2025.109238_bb0255","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1038\/s41568-020-0273-y","article-title":"Metabolism of immune cells in cancer","volume":"20","author":"Leone","year":"2020","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.bioorg.2025.109238_bb0260","doi-asserted-by":"crossref","unstructured":"F. Villarroel-Espindola, X. Yu, I. Datar, N. Mani, M. Sanmamed, V. Velcheti, K. Syrigos, M. Toki, H. Zhao, L. Chen, R.S. Herbst, K.A. Schalper, Spatially Resolved and Quantitative Analysis of VISTA\/PD-1H as a Novel Immunotherapy Target in Human Non\u2013Small Cell Lung Cancer, Clin. Cancer Res. 24 (2018) 1562\u20131573. Doi: https:\/\/doi.org\/10.1158\/1078-0432.CCR-17-2542.","DOI":"10.1158\/1078-0432.CCR-17-2542"},{"key":"10.1016\/j.bioorg.2025.109238_bb0265","doi-asserted-by":"crossref","first-page":"1666","DOI":"10.1038\/modpathol.2017.89","article-title":"Negative immune checkpoint regulation by VISTA: a mechanism of acquired resistance to anti-PD-1 therapy in metastatic melanoma patients","volume":"30","author":"Kakavand","year":"2017","journal-title":"Mod. Pathol."},{"key":"10.1016\/j.bioorg.2025.109238_bb0270","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1186\/s13045-022-01325-0","article-title":"Immune checkpoint modulators in cancer immunotherapy: recent advances and emerging concepts","volume":"15","author":"Wang","year":"2022","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.bioorg.2025.109238_bb0275","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1038\/s42003-021-02191-1","article-title":"PD-1 derived CA-170 is an oral immune checkpoint inhibitor that exhibits preclinical anti-tumor efficacy","volume":"4","author":"Sasikumar","year":"2021","journal-title":"Commun. Biol."},{"key":"10.1016\/j.bioorg.2025.109238_bb0280","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1021\/acsmedchemlett.9b00221","article-title":"In vitro assessment of putative PD-1\/PD-L1 inhibitors: suggestions of an alternative mode of action","volume":"10","author":"Blevins","year":"2019","journal-title":"ACS Med. Chem. Lett."},{"key":"10.1016\/j.bioorg.2025.109238_bb0285","doi-asserted-by":"crossref","first-page":"2804","DOI":"10.3390\/molecules24152804","article-title":"CA-170 \u2013 a potent small-molecule PD-L1 inhibitor or not?","volume":"24","author":"Musielak","year":"2019","journal-title":"Molecules"},{"key":"10.1016\/j.bioorg.2025.109238_bb0290","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41598-019-48826-6","article-title":"Comprehensive in vitro characterization of PD-L1 small molecule inhibitors","volume":"9","author":"Ganesan","year":"2019","journal-title":"Sci. Rep."},{"key":"10.1016\/j.bioorg.2025.109238_bb0295","doi-asserted-by":"crossref","first-page":"18526","DOI":"10.1021\/acs.jmedchem.4c01899","article-title":"Discovery of benzo[d]oxazoles as novel dual small-molecule inhibitors targeting PD-1\/PD-L1 and VISTA pathway","volume":"67","author":"Wang","year":"2024","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bioorg.2025.109238_bb0300","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1021\/acs.jmedchem.4c01640","article-title":"Novel PD-L1\/VISTA dual inhibitor as potential immunotherapy agents","volume":"68","author":"Sun","year":"2025","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bioorg.2025.109238_bb0310","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2025.108323","article-title":"Discovery of bifunctional small molecules targeting PD-L1\/VISTA with favorable pharmacokinetics for cancer immunotherapy","volume":"157","author":"Xiao","year":"2025","journal-title":"Bioorg. Chem."},{"key":"10.1016\/j.bioorg.2025.109238_bb0325","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1038\/s44321-024-00051-z","article-title":"The regulatory relationship between NAMPT and PD-L1 in cancer and identification of a dual-targeting inhibitor","volume":"16","author":"Yang","year":"2024","journal-title":"EMBO Mol. Med."},{"key":"10.1016\/j.bioorg.2025.109238_bb0345","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2025.117966","article-title":"Rational design of NAMPT-based dual inhibitors with improved drug-like and pharmacokinetic properties for cancer treatment","volume":"297","author":"Lv","year":"2025","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.bioorg.2025.109238_bb0370","first-page":"2022","article-title":"Bifunctional small molecules targeting PD-L1\/CXCL12 as dual immunotherapy for cancer treatment","volume":"8","author":"Cheng","year":"2023","journal-title":"Signal Transduct. Target. Ther."},{"key":"10.1016\/j.bioorg.2025.109238_bb0400","doi-asserted-by":"crossref","first-page":"9447","DOI":"10.1021\/acs.jmedchem.4c00553","article-title":"Discovery of small and bifunctional molecules targeting PD-L1\/CD73 for Cancer dual immunotherapy","volume":"67","author":"Wang","year":"2024","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bioorg.2025.109238_bb0440","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12964-024-01555-4","article-title":"Discovery of a novel small molecule as CD47\/SIRP\u03b1 and PD-1\/PD-L1 dual inhibitor for cancer immunotherapy","volume":"22","author":"Jin","year":"2024","journal-title":"Cell Commun. Signal"},{"key":"10.1016\/j.bioorg.2025.109238_bb0305","doi-asserted-by":"crossref","first-page":"3590","DOI":"10.1021\/acs.jmedchem.3c02039","article-title":"Design, synthesis, and antitumor activity evaluation of novel VISTA small molecule inhibitors","volume":"67","author":"Sun","year":"2024","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bioorg.2025.109238_bb0315","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2021.109516","article-title":"NAD+ supplement potentiates tumor-killing function by rescuing defective TUB-mediated NAMPT transcription in tumor-infiltrated T cells","volume":"36","author":"Wang","year":"2021","journal-title":"Cell Rep."},{"key":"10.1016\/j.bioorg.2025.109238_bb0320","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/j.cmet.2020.10.021","article-title":"NAD(+) metabolism maintains inducible PD-L1 expression to drive tumor immune evasion","volume":"33","author":"Lv","year":"2021","journal-title":"Cell Metab."},{"key":"10.1016\/j.bioorg.2025.109238_bb0330","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2019.111856","article-title":"Discovery of the programmed cell death-1\/programmed cell death-ligand 1 interaction inhibitors bearing an indoline scaffold","volume":"186","author":"Qin","year":"2020","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.bioorg.2025.109238_bb0335","doi-asserted-by":"crossref","first-page":"5519","DOI":"10.1021\/acs.jmedchem.0c01958","article-title":"Discovery of 4-Arylindolines containing a Thiazole moiety as potential antitumor agents inhibiting the programmed cell Death-1\/programmed cell death-ligand 1 interaction","volume":"64","author":"Qin","year":"2021","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bioorg.2025.109238_bb0340","doi-asserted-by":"crossref","DOI":"10.1016\/j.bmc.2024.117595","article-title":"Drug discovery targeting nicotinamide phosphoribosyltransferase (NAMPT): updated progress and perspectives","volume":"99","author":"Wen","year":"2024","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.bioorg.2025.109238_bb0350","doi-asserted-by":"crossref","first-page":"7390","DOI":"10.1021\/acs.jmedchem.1c00010","article-title":"Novel biphenyl pyridines as potent small-molecule inhibitors targeting the programmed cell Death-1\/programmed cell death-ligand 1 interaction","volume":"64","author":"Wang","year":"2021","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bioorg.2025.109238_bb0355","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2020.574667","article-title":"The role of the CXCL12\/CXCR4\/CXCR7 chemokine Axis in Cancer","volume":"11","author":"Shi","year":"2020","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.bioorg.2025.109238_bb0360","doi-asserted-by":"crossref","first-page":"20212","DOI":"10.1073\/pnas.1320318110","article-title":"Targeting CXCL12 from FAP-expressing carcinoma-associated fibroblasts synergizes with anti-PD-L1 immunotherapy in pancreatic cancer","volume":"110","author":"Feig","year":"2013","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.bioorg.2025.109238_bb0365","doi-asserted-by":"crossref","first-page":"6596","DOI":"10.1096\/fj.201802067RR","article-title":"Dual blockade of CXCL12-CXCR4 and PD-1-PD-L1 pathways prolongs survival of ovarian tumor-bearing mice by prevention of immunosuppression in the tumor microenvironment","volume":"33","author":"Zeng","year":"2019","journal-title":"FASEB J."},{"key":"10.1016\/j.bioorg.2025.109238_bb0375","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1080\/14728222.2019.1559829","article-title":"CD73 as a potential opportunity for cancer immunotherapy","volume":"23","author":"Ghalamfarsa","year":"2019","journal-title":"Expert Opin. Ther. Targets"},{"key":"10.1016\/j.bioorg.2025.109238_bb0380","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.coph.2020.07.001","article-title":"Targeting CD73 to augment cancer immunotherapy","volume":"53","author":"Roh","year":"2020","journal-title":"Curr. Opin. Pharmacol."},{"key":"10.1016\/j.bioorg.2025.109238_bb0385","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1016\/j.jcmgh.2022.07.005","article-title":"Additive effect of CD73 inhibitor in colorectal Cancer treatment with CDK4\/6 inhibitor through regulation of PD-L1","volume":"14","author":"Noh","year":"2022","journal-title":"Cell. Mol. Gastroenterol. Hepatol."},{"key":"10.1016\/j.bioorg.2025.109238_bb0390","doi-asserted-by":"crossref","first-page":"1565","DOI":"10.3390\/ijms23031565","article-title":"CD73 and PD-L1 as potential therapeutic targets in gallbladder Cancer","volume":"23","author":"Cao","year":"2022","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.bioorg.2025.109238_bb0395","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3389\/fimmu.2023.1212209","article-title":"Inhibitors of the CD73-adenosinergic checkpoint as promising combinatory agents for conventional and advanced cancer immunotherapy","volume":"14","author":"Kurago","year":"2023","journal-title":"Front. Immunol."},{"key":"10.1016\/j.bioorg.2025.109238_bb0405","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1016\/j.immuni.2020.04.011","article-title":"The CD47-SIRP\u03b1 immune checkpoint","volume":"52","author":"Logtenberg","year":"2020","journal-title":"Immunity"},{"key":"10.1016\/j.bioorg.2025.109238_bb0410","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1016\/j.blre.2018.04.005","article-title":"Blocking \u201cdon't eat me\u201d signal of CD47-SIRP\u03b1 in hematological malignancies, an in-depth review","volume":"32","author":"Russ","year":"2018","journal-title":"Blood Rev."},{"key":"10.1016\/j.bioorg.2025.109238_bb0415","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2023.116014","article-title":"The role of tumor-associated macrophages in lung cancer: from mechanism to small molecule therapy","volume":"170","author":"Zhou","year":"2024","journal-title":"Biomed. Pharmacother."},{"key":"10.1016\/j.bioorg.2025.109238_bb0420","doi-asserted-by":"crossref","first-page":"2310","DOI":"10.1007\/s11427-022-2285-6","article-title":"Design of a novel chimeric peptide via dual blockade of CD47\/SIRP\u03b1 and PD-1\/PD-L1 for cancer immunotherapy","volume":"66","author":"Hu","year":"2023","journal-title":"Sci. China Life Sci."},{"key":"10.1016\/j.bioorg.2025.109238_bb0425","doi-asserted-by":"crossref","first-page":"2101","DOI":"10.1016\/j.celrep.2018.07.062","article-title":"Dual targeting of innate and adaptive checkpoints on tumor cells limits immune evasion","volume":"24","author":"Liu","year":"2018","journal-title":"Cell Rep."},{"key":"10.1016\/j.bioorg.2025.109238_bb0430","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1007\/s00262-020-02679-5","article-title":"Tumor-selective blockade of CD47 signaling with a CD47\/PD-L1 bispecific antibody for enhanced anti-tumor activity and limited toxicity","volume":"70","author":"Wang","year":"2021","journal-title":"Cancer Immunol. Immunother."},{"key":"10.1016\/j.bioorg.2025.109238_bb0435","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1111\/imm.13498","article-title":"Advances in the study of CD47-based bispecific antibody in cancer immunotherapy","volume":"167","author":"Zhang","year":"2022","journal-title":"Immunology"},{"key":"10.1016\/j.bioorg.2025.109238_bb0450","doi-asserted-by":"crossref","DOI":"10.1016\/j.lfs.2021.119504","article-title":"Epigenetic modulation and understanding of HDAC inhibitors in cancer therapy","volume":"277","author":"Ramaiah","year":"2021","journal-title":"Life Sci."},{"key":"10.1016\/j.bioorg.2025.109238_bb0455","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1038\/s41392-024-01823-2","article-title":"Tumor biomarkers for diagnosis, prognosis and targeted therapy","volume":"9","author":"Zhou","year":"2024","journal-title":"Signal Transduct. Target. Ther."},{"key":"10.1016\/j.bioorg.2025.109238_bb0460","doi-asserted-by":"crossref","DOI":"10.1016\/j.drudis.2022.103435","article-title":"PD-L1 small-molecule modulators: a new hope in epigenetic-based multidrug cancer therapy?","volume":"28","author":"Zwergel","year":"2023","journal-title":"Drug Discov. Today"},{"key":"10.1016\/j.bioorg.2025.109238_bb0465","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1038\/leu.2017.322","article-title":"Combination of a novel HDAC6 inhibitor ACY-241 and anti-PD-L1 antibody enhances anti-tumor immunity and cytotoxicity in multiple myeloma","volume":"32","author":"Ray","year":"2018","journal-title":"Leukemia"},{"key":"10.1016\/j.bioorg.2025.109238_bb0470","doi-asserted-by":"crossref","first-page":"eaaz6804","DOI":"10.1126\/scitranslmed.aaz6804","article-title":"A selective HDAC8 inhibitor potentiates antitumor immunity and efficacy of immune checkpoint blockade in hepatocellular carcinoma","volume":"13","author":"Yang","year":"2021","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.bioorg.2025.109238_bb0475","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1170207","article-title":"HDAC inhibitors enhance the anti-tumor effect of immunotherapies in hepatocellular carcinoma","volume":"14","author":"Shen","year":"2023","journal-title":"Front. Immunol."},{"key":"10.1016\/j.bioorg.2025.109238_bb0480","doi-asserted-by":"crossref","first-page":"2434","DOI":"10.1021\/acs.jmedchem.1c01863","article-title":"Discovery of novel histone deacetylase 6 (HDAC6) inhibitors with enhanced antitumor immunity of anti-PD-L1 immunotherapy in melanoma","volume":"65","author":"Peng","year":"2022","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bioorg.2025.109238_bb0485","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2023.115673","article-title":"A review of progress in o-aminobenzamide-based HDAC inhibitors with dual targeting capabilities for cancer therapy","volume":"259","author":"Zhang","year":"2023","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.bioorg.2025.109238_bb0490","doi-asserted-by":"crossref","DOI":"10.1016\/j.bmc.2021.116510","article-title":"From natural products to HDAC inhibitors: an overview of drug discovery and design strategy","volume":"52","author":"Qiu","year":"2021","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.bioorg.2025.109238_bb0495","doi-asserted-by":"crossref","first-page":"13067","DOI":"10.1021\/acs.jmedchem.4c01062","article-title":"Discovery of novel HDAC3 inhibitors with PD-L1 downregulating\/degrading and antitumor immune effects","volume":"67","author":"Sun","year":"2024","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bioorg.2025.109238_bb0500","doi-asserted-by":"crossref","first-page":"5426","DOI":"10.1021\/acs.jmedchem.4c02510","article-title":"Discovery of novel and highly potent dual PD-L1\/histone deacetylase 6 inhibitors with favorable pharmacokinetics for Cancer immunotherapy","volume":"68","author":"Hu","year":"2025","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bioorg.2025.109238_bb0505","doi-asserted-by":"crossref","first-page":"8046","DOI":"10.1021\/acs.jmedchem.4c02529","article-title":"Discovery of dual PD-L1\/HDAC3 inhibitors for tumor immunotherapy","volume":"68","author":"Wang","year":"2025","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bioorg.2025.109238_bb0515","doi-asserted-by":"crossref","DOI":"10.1080\/14756366.2025.2461190","article-title":"Discovery of novel biphenyl compounds bearing hydroxamic acid moiety as the first PD-L1\/class I HDACs dual inhibitors","volume":"40","author":"Yuan","year":"2025","journal-title":"J. Enzyme Inhib. Med. Chem."},{"key":"10.1016\/j.bioorg.2025.109238_bb0555","doi-asserted-by":"crossref","first-page":"12584","DOI":"10.1021\/acsomega.9b01106","article-title":"Small-molecule poly(ADP-ribose) polymerase and PD-L1 inhibitor conjugates as dual-action anticancer agents","volume":"4","author":"Ofori","year":"2019","journal-title":"ACS Omega"},{"key":"10.1016\/j.bioorg.2025.109238_bb0560","doi-asserted-by":"crossref","first-page":"10848","DOI":"10.1021\/acs.jmedchem.4c00296","article-title":"Novel bifunctional conjugates targeting PD-L1\/PARP7 as dual immunotherapy for potential Cancer treatment","volume":"67","author":"Gao","year":"2024","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bioorg.2025.109238_bb0670","doi-asserted-by":"crossref","first-page":"7995","DOI":"10.1021\/acs.jmedchem.4c00128","article-title":"Discovery of novel small-molecule-based potential PD-L1\/EGFR dual inhibitors with high Druggability for glioblastoma immunotherapy","volume":"67","author":"Yang","year":"2024","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bioorg.2025.109238_bb0690","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2020.113058","article-title":"Discovery of novel CA-4 analogs as dual inhibitors of tubulin polymerization and PD-1\/PD-L1 interaction for cancer treatment","volume":"213","author":"Yang","year":"2021","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.bioorg.2025.109238_bb0510","doi-asserted-by":"crossref","first-page":"9942","DOI":"10.1021\/acs.jmedchem.6b01385","article-title":"Development of allosteric hydrazide-containing class i histone deacetylase inhibitors for use in acute myeloid leukemia","volume":"59","author":"McClure","year":"2016","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bioorg.2025.109238_bb0520","doi-asserted-by":"crossref","first-page":"1437","DOI":"10.1093\/annonc\/mdz192","article-title":"A decade of clinical development of PARP inhibitors in perspective","volume":"30","author":"Mateo","year":"2019","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.bioorg.2025.109238_bb0525","doi-asserted-by":"crossref","first-page":"7532","DOI":"10.1021\/acs.jmedchem.2c00281","article-title":"Medicinal chemistry perspective on targeting mono-ADP-Ribosylating PARPs with small molecules","volume":"65","author":"Nizi","year":"2022","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bioorg.2025.109238_bb0530","doi-asserted-by":"crossref","first-page":"3000","DOI":"10.1200\/JCO.2021.39.15_suppl.3000","article-title":"A first-in-human phase 1 study of a novel PARP7 inhibitor RBN-2397 in patients with advanced solid tumors","volume":"39","author":"Falchook","year":"2025","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.bioorg.2025.109238_bb0535","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2019.109790","article-title":"IFI16 promotes cervical cancer progression by upregulating PD-L1 in immunomicroenvironment through STING-TBK1-NF-kB pathway","volume":"123","author":"Cai","year":"2020","journal-title":"Biomed. Pharmacother."},{"key":"10.1016\/j.bioorg.2025.109238_bb0540","doi-asserted-by":"crossref","first-page":"3711","DOI":"10.1158\/1078-0432.CCR-16-3215","article-title":"PARP inhibitor upregulates PD-L1 expression and enhances cancer-associated immunosuppression","volume":"23","author":"Jiao","year":"2017","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.bioorg.2025.109238_bb0545","doi-asserted-by":"crossref","first-page":"2166","DOI":"10.1038\/s41467-025-57257-z","article-title":"PARP inhibitor radiosensitization enhances anti-PD-L1 immunotherapy through stabilizing chemokine mRNA in small cell lung cancer","volume":"16","author":"Ran","year":"2025","journal-title":"Nat. Commun."},{"key":"10.1016\/j.bioorg.2025.109238_bb0550","unstructured":"J.Y. CHEN Siyu, SUN Wei, Research Progress in combined application of PARP inhibitors and PD-1\/PD-L1 inhibitors in malignant tumors, Chinese Pharm. J. 58 (2023) 2235\u2013239. Doi: 10.11669\/cpj.2023.24.007."},{"key":"10.1016\/j.bioorg.2025.109238_bb0565","doi-asserted-by":"crossref","first-page":"6901","DOI":"10.2147\/OTT.S172042","article-title":"Targeting VEGF pathway to normalize the vasculature: an emerging insight in cancer therapy","volume":"11","author":"Wu","year":"2018","journal-title":"Onco. Targets. Ther."},{"key":"10.1016\/j.bioorg.2025.109238_bb0570","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1186\/s13046-021-02069-4","article-title":"Apatinib triggers autophagic and apoptotic cell death via VEGFR2\/STAT3\/PD-L1 and ROS\/Nrf2\/p62 signaling in lung cancer","volume":"40","author":"Xie","year":"2021","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"10.1016\/j.bioorg.2025.109238_bb0575","doi-asserted-by":"crossref","first-page":"1247","DOI":"10.1002\/hep.30889","article-title":"Dual programmed death Receptor-1 and vascular endothelial growth factor Receptor-2 blockade promotes vascular normalization and enhances antitumor immune responses in hepatocellular carcinoma","volume":"71","author":"Shigeta","year":"2020","journal-title":"Hepatology"},{"key":"10.1016\/j.bioorg.2025.109238_bb0580","first-page":"338","article-title":"Dual vascular endothelial growth factor receptor and fibroblast growth factor receptor inhibition elicits antitumor immunity and enhances programmed cell Death-1 checkpoint blockade in hepatocellular carcinoma., liver","volume":"9","author":"Deng","year":"2020","journal-title":"Cancer"},{"key":"10.1016\/j.bioorg.2025.109238_bb0585","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2021.111607","article-title":"Vascular normalization in immunotherapy: a promising mechanisms combined with radiotherapy","volume":"139","author":"Liu","year":"2021","journal-title":"Biomed. Pharmacother."},{"key":"10.1016\/j.bioorg.2025.109238_bb0590","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/j.ejmech.2019.03.012","article-title":"Novel multitarget inhibitors with antiangiogenic and immunomodulator properties","volume":"170","author":"Conesa-Mili\u00e1n","year":"2019","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.bioorg.2025.109238_bb0595","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1155\/2013\/739574","article-title":"Molecular dynamics simulation of VEGFR2 with Sorafenib and other urea-substituted Aryloxy compounds","volume":"2013","author":"Meng","year":"2013","journal-title":"J. Theor. Chem."},{"key":"10.1016\/j.bioorg.2025.109238_bb0600","doi-asserted-by":"crossref","first-page":"18281","DOI":"10.1073\/pnas.1207759109","article-title":"Molecular conformations, interactions, and properties associated with drug efficiency and clinical performance among VEGFR TK inhibitors","volume":"109","author":"McTigue","year":"2012","journal-title":"Proc. Natl. Acad. Sci."},{"key":"10.1016\/j.bioorg.2025.109238_bb0605","doi-asserted-by":"crossref","first-page":"337","DOI":"10.3390\/ph14040337","article-title":"Aryl urea based scaffolds for multitarget drug discovery in anticancer immunotherapies","volume":"14","author":"Mart\u00edn-Beltr\u00e1n","year":"2021","journal-title":"Pharmaceuticals"},{"key":"10.1016\/j.bioorg.2025.109238_bb0610","doi-asserted-by":"crossref","first-page":"7049","DOI":"10.3390\/ijms23137049","article-title":"Synthesis and biological evaluation of small molecules as potential anticancer multitarget agents","volume":"23","author":"Pla-L\u00f3pez","year":"2022","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.bioorg.2025.109238_bb0615","doi-asserted-by":"crossref","DOI":"10.1016\/j.bmc.2023.117490","article-title":"Aryl azoles based scaffolds for disrupting tumor microenvironment","volume":"95","author":"Pla-L\u00f3pez","year":"2023","journal-title":"Bioorganic Med. Chem."},{"key":"10.1016\/j.bioorg.2025.109238_bb0620","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2023.115668","article-title":"Tetrazole derivatives as potent immunomodulatory agents in tumor microenvironment","volume":"169","author":"Pla-L\u00f3pez","year":"2023","journal-title":"Biomed. Pharmacother."},{"key":"10.1016\/j.bioorg.2025.109238_bb0625","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3390\/ph16060808","article-title":"Unveiling the potential of BenzylethyleneAryl\u2013urea scaffolds for the Design of new Onco Immunomodulating Agents","volume":"16","author":"Gil-Edo","year":"2023","journal-title":"Pharmaceuticals"},{"key":"10.1016\/j.bioorg.2025.109238_bb0630","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1002\/hep.29350","article-title":"Role of ErbB\/HER family of receptor tyrosine kinases in cholangiocyte biology","volume":"67","author":"Pellat","year":"2018","journal-title":"Hepatology"},{"key":"10.1016\/j.bioorg.2025.109238_bb0635","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1016\/j.cell.2012.02.063","article-title":"Oncogenic mutations counteract intrinsic disorder in the EGFR kinase and promote receptor dimerization","volume":"149","author":"Shan","year":"2012","journal-title":"Cell"},{"key":"10.1016\/j.bioorg.2025.109238_bb0640","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1080\/14737140.2019.1596030","article-title":"Epidermal growth factor receptor tyrosine kinase inhibitors for the treatment of non-small cell lung cancer","volume":"19","author":"Kujtan","year":"2019","journal-title":"Expert Rev. Anticancer Ther."},{"key":"10.1016\/j.bioorg.2025.109238_bb0645","doi-asserted-by":"crossref","first-page":"6844","DOI":"10.1021\/acs.jmedchem.5b01082","article-title":"Targeting drug resistance in EGFR with covalent inhibitors: a structure-based design approach","volume":"58","author":"Engel","year":"2015","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bioorg.2025.109238_bb0650","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1038\/nature17960","article-title":"Overcoming EGFR(T790M) and EGFR(C797S) resistance with mutant-selective allosteric inhibitors","volume":"534","author":"Jia","year":"2016","journal-title":"Nature"},{"key":"10.1016\/j.bioorg.2025.109238_bb0655","first-page":"910","article-title":"Upregulation of PD-L1 by EGFR activation mediates the immune escape in EGFR-driven NSCLC: implication for optional immune targeted therapy for NSCLC patients with EGFR mutation., J. Thorac. Oncol. Off. Publ. Int. Assoc. study","volume":"10","author":"Chen","year":"2015","journal-title":"Lung Cancer"},{"key":"10.1016\/j.bioorg.2025.109238_bb0660","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.canlet.2018.01.005","article-title":"Interactions between EGFR and PD-1\/PD-L1 pathway: implications for treatment of NSCLC","volume":"418","author":"Li","year":"2018","journal-title":"Cancer Lett."},{"key":"10.1016\/j.bioorg.2025.109238_bb0665","doi-asserted-by":"crossref","first-page":"3392","DOI":"10.7150\/thno.52435","article-title":"ILT4 inhibition prevents TAM- and dysfunctional T cell-mediated immunosuppression and enhances the efficacy of anti-PD-L1 therapy in NSCLC with EGFR activation","volume":"11","author":"Chen","year":"2021","journal-title":"Theranostics"},{"key":"10.1016\/j.bioorg.2025.109238_bb0675","doi-asserted-by":"crossref","first-page":"2086","DOI":"10.1158\/1535-7163.MCT-09-0366","article-title":"Microtubule inhibitors: differentiating tubulin-inhibiting agents based on mechanisms of action, clinical activity, and resistance","volume":"8","author":"Perez","year":"2009","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.bioorg.2025.109238_bb0680","doi-asserted-by":"crossref","DOI":"10.1016\/j.bmcl.2024.130037","article-title":"Recent advances of selenized tubulin inhibitors in cancer therapy","volume":"116","author":"Zhao","year":"2025","journal-title":"Bioorganic Med. Chem. Lett."},{"key":"10.1016\/j.bioorg.2025.109238_bb0685","doi-asserted-by":"crossref","DOI":"10.1016\/j.bmc.2020.115684","article-title":"A 2-step synthesis of Combretastatin A-4 and derivatives as potent tubulin assembly inhibitors","volume":"28","author":"Barnes","year":"2020","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.bioorg.2025.109238_bb0695","doi-asserted-by":"crossref","first-page":"7963","DOI":"10.1021\/acs.jmedchem.1c00100","article-title":"Recent Progress on tubulin inhibitors with dual targeting capabilities for Cancer therapy","volume":"64","author":"Shuai","year":"2021","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bioorg.2025.109238_bb0700","doi-asserted-by":"crossref","first-page":"1398","DOI":"10.1002\/med.21568","article-title":"Current advances of tubulin inhibitors as dual acting small molecules for cancer therapy","volume":"39","author":"Arnst","year":"2019","journal-title":"Med. Res. Rev."},{"key":"10.1016\/j.bioorg.2025.109238_bb0705","doi-asserted-by":"crossref","DOI":"10.1016\/j.phymed.2024.155444","article-title":"Protoberberine alkaloids: a review of the gastroprotective effects, pharmacokinetics, and toxicity","volume":"126","author":"Xiang","year":"2024","journal-title":"Phytomedicine"},{"key":"10.1016\/j.bioorg.2025.109238_bb0710","doi-asserted-by":"crossref","first-page":"2299","DOI":"10.1016\/j.apsb.2020.06.014","article-title":"Berberine diminishes cancer cell PD-L1 expression and facilitates antitumor immunity via inhibiting the deubiquitination activity of CSN5","volume":"10","author":"Liu","year":"2020","journal-title":"Acta Pharm. Sin. B"},{"key":"10.1016\/j.bioorg.2025.109238_bb0715","first-page":"1","article-title":"Berberine derivative B68 promotes tumor immune clearance by dual-targeting BMI1 for senescence induction and CSN5 for PD-L1 degradation","volume":"2413122","author":"Hu","year":"2024","journal-title":"Adv. Sci."},{"key":"10.1016\/j.bioorg.2025.109238_bb0720","doi-asserted-by":"crossref","first-page":"19216","DOI":"10.1021\/acs.jmedchem.4c01652","article-title":"Advancing Cancer immunotherapy through engineering new PD-L1 degraders: a comprehensive study from small molecules to PD-L1-specific peptide-drug conjugates","volume":"67","author":"Zeng","year":"2024","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bioorg.2025.109238_bb0725","doi-asserted-by":"crossref","first-page":"eadq3940","DOI":"10.1126\/sciadv.adq3940","article-title":"Tumor-specific delivery of clickable inhibitor for PD-L1 degradation and mitigating resistance of radioimmunotherapy","volume":"10","author":"Hou","year":"2024","journal-title":"Sci. Adv."},{"key":"10.1016\/j.bioorg.2025.109238_bb0740","first-page":"1","article-title":"A covalent peptide-based lysosome-targeting protein degradation platform for cancer immunotherapy","volume":"16","author":"Xiao","year":"2025","journal-title":"Nat. Commun."},{"key":"10.1016\/j.bioorg.2025.109238_bb0785","doi-asserted-by":"crossref","first-page":"11829","DOI":"10.1021\/acs.jmedchem.5c00675","article-title":"A DNA-mediated lysosomal degradation strategy for targeted degradation of PD-L1 protein","volume":"68","author":"Huang","year":"2025","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bioorg.2025.109238_bb0790","doi-asserted-by":"crossref","first-page":"2156","DOI":"10.1016\/j.apsb.2025.02.037","article-title":"GPC3-mediated lysosome-targeting chimeras (GLTACs) for targeted degradation of membrane proteins","volume":"15","author":"Fang","year":"2025","journal-title":"Acta Pharm. Sin. B"},{"key":"10.1016\/j.bioorg.2025.109238_bb0820","article-title":"Engineered platelets as targeted protein degraders and application to breast cancer models","author":"Chen","year":"2024","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.bioorg.2025.109238_bb0830","doi-asserted-by":"crossref","first-page":"12641","DOI":"10.1021\/acs.jmedchem.5c00379","article-title":"Extracellular HSP90-facilitated degradation of extracellular and membrane proteins by bifunctional small molecules","volume":"26","author":"Zhang","year":"2025","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bioorg.2025.109238_bb0730","doi-asserted-by":"crossref","first-page":"1821","DOI":"10.1073\/pnas.0911116107","article-title":"Copper-free click chemistry in living animals","volume":"107","author":"Chang","year":"2010","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.bioorg.2025.109238_bb0735","doi-asserted-by":"crossref","first-page":"1102","DOI":"10.1038\/s41557-020-00587-w","article-title":"Metabolic glycan labelling for cancer-targeted therapy","volume":"12","author":"Wang","year":"2020","journal-title":"Nat. Chem."},{"key":"10.1016\/j.bioorg.2025.109238_bb0745","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1016\/j.metabol.2014.03.011","article-title":"Scavenger receptor class B type I (SR-BI): a versatile receptor with multiple functions and actions","volume":"63","author":"Shen","year":"2014","journal-title":"Metabolism"},{"key":"10.1016\/j.bioorg.2025.109238_bb0750","doi-asserted-by":"crossref","first-page":"3198","DOI":"10.4049\/jimmunol.1600438","article-title":"Scavenger receptor SCARA5 acts as an HMGB1 recognition molecule negatively involved in HMGB1-mediated inflammation in fish models","volume":"197","author":"Guo","year":"2016","journal-title":"J. Immunol."},{"key":"10.1016\/j.bioorg.2025.109238_bb0755","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/j.ymeth.2007.06.004","article-title":"Macrophage scavenger receptors and host-derived ligands","volume":"43","author":"Pl\u00fcddemann","year":"2007","journal-title":"Methods"},{"key":"10.1016\/j.bioorg.2025.109238_bb0760","doi-asserted-by":"crossref","first-page":"6459","DOI":"10.1021\/acs.chemrev.7b00663","article-title":"DNA nanotechnology-enabled drug delivery systems","volume":"119","author":"Hu","year":"2019","journal-title":"Chem. Rev."},{"key":"10.1016\/j.bioorg.2025.109238_bb0765","doi-asserted-by":"crossref","first-page":"3631","DOI":"10.1021\/acsnano.0c06136","article-title":"Current challenges and opportunities for cellular delivery","volume":"15","author":"Lacroix","year":"2021","journal-title":"ACS Nano"},{"key":"10.1016\/j.bioorg.2025.109238_bb0770","doi-asserted-by":"crossref","first-page":"6946","DOI":"10.1021\/acs.nanolett.1c02191","article-title":"DNA nanostructure-programmed cell entry via corner angle-mediated molecular interaction with membrane receptors","volume":"21","author":"Peng","year":"2021","journal-title":"Nano Lett."},{"key":"10.1016\/j.bioorg.2025.109238_bb0775","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1021\/acschembio.3c00645","article-title":"Targeted extracellular protein degradation by Dendronized DNA chimeras","volume":"19","author":"Zhu","year":"2024","journal-title":"ACS Chem. Biol."},{"key":"10.1016\/j.bioorg.2025.109238_bb0780","article-title":"Dendronized DNA chimeras harness scavenger receptors to degrade cell membrane proteins","volume":"62","author":"Zhu","year":"2023","journal-title":"Angew. Chemie - Int. Ed."},{"key":"10.1016\/j.bioorg.2025.109238_bb0795","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1038\/nrc1716","article-title":"HSP90 and the chaperoning of cancer","volume":"5","author":"Whitesell","year":"2005","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.bioorg.2025.109238_bb0800","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1038\/nchembio.670","article-title":"Affinity-based proteomics reveal cancer-specific networks coordinated by Hsp90","volume":"7","author":"Moulick","year":"2011","journal-title":"Nat. Chem. Biol."},{"key":"10.1016\/j.bioorg.2025.109238_bb0805","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2024.116736","article-title":"Extracellular heat shock protein 90 alpha (eHsp90\u03b1)\u2019s role in cancer progression and the development of therapeutic strategies","volume":"277","author":"Reynolds","year":"2024","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.bioorg.2025.109238_bb0810","doi-asserted-by":"crossref","first-page":"1632","DOI":"10.1021\/jacsau.4c00123","article-title":"Accurate characterization of binding kinetics and allosteric mechanisms for the HSP90 chaperone inhibitors using AI-augmented integrative biophysical studies","volume":"4","author":"Xu","year":"2024","journal-title":"JACS Au"},{"key":"10.1016\/j.bioorg.2025.109238_bb0815","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2022.114516","article-title":"Pan- and isoform-specific inhibition of Hsp90: design strategy and recent advances","volume":"238","author":"Yu","year":"2022","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.bioorg.2025.109238_bb0825","doi-asserted-by":"crossref","first-page":"eabb0020","DOI":"10.1126\/sciadv.abb0020","article-title":"Vascular disrupting agent induced aggregation of gold nanoparticles for photothermally enhanced tumor vascular disruption","volume":"6","author":"Hong","year":"2020","journal-title":"Sci. Adv."},{"key":"10.1016\/j.bioorg.2025.109238_bb0835","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12943-024-02024-9","article-title":"New-generation advanced PROTACs as potential therapeutic agents in cancer therapy","volume":"23","author":"Wang","year":"2024","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.bioorg.2025.109238_bb0840","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2025.108846","article-title":"Application of proteolysis targeting chimeric (PROTAC) technology in protein regulation and drug development","volume":"164","author":"He","year":"2025","journal-title":"Bioorg. Chem."},{"key":"10.1016\/j.bioorg.2025.109238_bb0845","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2025.108794","article-title":"Stromal reprogramming in solid tumors by nanoparticles: a review","volume":"163","author":"Altalbawy","year":"2025","journal-title":"Bioorg. Chem."},{"key":"10.1016\/j.bioorg.2025.109238_bb0850","doi-asserted-by":"crossref","DOI":"10.1002\/cmdc.202500179","article-title":"Progress in the Research and Development of biphenyl small molecules targeting PD-1\/PD-L1 as potential antitumor drug candidates","volume":"20","author":"He","year":"2025","journal-title":"ChemMedChem"},{"key":"10.1016\/j.bioorg.2025.109238_bb0855","first-page":"1575","article-title":"Resistance mechanisms to programmed cell death protein 1 and programmed death ligand 1 inhibitors, expert Opin","volume":"21","author":"Pezeshki","year":"2021","journal-title":"Biol. Ther."},{"key":"10.1016\/j.bioorg.2025.109238_bb0860","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.927265","article-title":"Combination approaches to target PD-1 signaling in Cancer","volume":"13","author":"Moore","year":"2022","journal-title":"Front. Immunol."},{"key":"10.1016\/j.bioorg.2025.109238_bb0865","doi-asserted-by":"crossref","DOI":"10.1016\/j.drup.2022.100907","article-title":"Research progress of therapeutic effects and drug resistance of immunotherapy based on PD-1\/PD-L1 blockade","volume":"66","author":"Pang","year":"2023","journal-title":"Drug Resist. Updat."},{"key":"10.1016\/j.bioorg.2025.109238_bb0870","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2024.117212","article-title":"Recent advances in developing targeted protein degraders","volume":"284","author":"Cheng","year":"2025","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.bioorg.2025.109238_bb0875","article-title":"Unconventional PROTACs for targeted protein degradation in Cancer therapy","volume":"64","author":"Zhang","year":"2025","journal-title":"Angew. Chemie - Int. Ed."},{"key":"10.1016\/j.bioorg.2025.109238_bb0880","doi-asserted-by":"crossref","first-page":"16377","DOI":"10.1021\/jacs.1c08521","article-title":"Covalently engineered Nanobody chimeras for targeted membrane protein degradation","volume":"143","author":"Zhang","year":"2021","journal-title":"J. Am. Chem. Soc."},{"key":"10.1016\/j.bioorg.2025.109238_bb0885","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1186\/s13045-025-01703-4","article-title":"Targeted degradation of extracellular proteins: state of the art and diversity of degrader designs","volume":"18","author":"Mamun","year":"2025","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.bioorg.2025.109238_bb0890","first-page":"597","article-title":"ROS-sensitive PD-L1 siRNA cationic selenide nanogels for self-inhibition of autophagy and prevention of immune escape","volume":"41","author":"Gao","year":"2024","journal-title":"Bioact. Mater."},{"key":"10.1016\/j.bioorg.2025.109238_bb0895","doi-asserted-by":"crossref","first-page":"3612","DOI":"10.1021\/acs.jmedchem.4c02747","article-title":"Simultaneous induction of immunogenic Pyroptosis and PD-L1 downregulation by one single photosensitizer for synergistic Cancer Photoimmunotherapy","volume":"68","author":"Chen","year":"2025","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bioorg.2025.109238_bb0900","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1016\/j.jconrel.2021.12.023","article-title":"Paclitaxel derivative-based liposomal nanoplatform for potentiated chemo-immunotherapy","volume":"341","author":"Wang","year":"2022","journal-title":"J. Control. Release"}],"container-title":["Bioorganic Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0045206825011186?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0045206825011186?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,12,18]],"date-time":"2025-12-18T21:19:04Z","timestamp":1766092744000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0045206825011186"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12]]},"references-count":179,"alternative-id":["S0045206825011186"],"URL":"https:\/\/doi.org\/10.1016\/j.bioorg.2025.109238","relation":{},"ISSN":["0045-2068"],"issn-type":[{"value":"0045-2068","type":"print"}],"subject":[],"published":{"date-parts":[[2025,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"PD-L1-targeted novel molecule design: recent advances in immunomodulatory technologies and emerging insights in Cancer therapy","name":"articletitle","label":"Article Title"},{"value":"Bioorganic Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bioorg.2025.109238","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"109238"}}